Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other equities analysts have also commented on ENOV. Citizens Jmp lowered their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Finally, Citigroup reissued a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

Enovis Stock Down 5.8%

Shares of Enovis stock opened at $18.17 on Friday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -0.94 and a beta of 1.31. Enovis has a twelve month low of $18.00 and a twelve month high of $34.28. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The business’s 50 day simple moving average is $25.10 and its 200-day simple moving average is $24.07.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the firm posted $0.79 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts forecast that Enovis will post 3.15 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Damien Mcdonald bought 13,035 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Oliver Engert bought 5,140 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were purchased at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the acquisition, the insider owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 23,293 shares of company stock worth $449,599 in the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new position in Enovis during the second quarter valued at about $39,000. IFP Advisors Inc raised its position in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after acquiring an additional 1,174 shares in the last quarter. Allworth Financial LP raised its position in Enovis by 59.7% in the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after acquiring an additional 652 shares in the last quarter. Amundi lifted its holdings in Enovis by 397.7% in the 2nd quarter. Amundi now owns 369,189 shares of the company’s stock valued at $7,642,000 after acquiring an additional 295,005 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Enovis in the 2nd quarter valued at about $559,000. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.